Once-daily oral treatment for your adult patients with active ankylosing spondylitis1
One dose, one tablet, once a day
Starting patients on RINVOQ
A convenient guide providing information on dosing, screening, monitoring and safety recommendations.
The recommended dose of RINVOQ is one 15-mg tablet once a day, with or without food
Tablets should be swallowed whole, and should not be split, crushed, or chewed
RINVOQ may be taken at any time of the day; patients may find it easier to take RINVOQ at the same time every day to help them remember to take it
Consideration should be given to discontinuing treatment in patients with ankylosing spondylitis who have shown no clinical response after 16 weeks of treatment. Some patients with initial partial response may subsequently improve with continued treatment beyond 16 weeks.
You are now leaving the AbbVie Pro Portal and being re-directed to an external website which is not under the control of AbbVie. AbbVie is not responsible for content of any such site or any further links from such site.
Reporting of side effects (patients and public in the UK)
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk.
By reporting side effects you can help provide more information on the safety of this medicine.
For medicines with black triangle: ▼ means the medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects.